Avammune Therapeutics, a India-based healthtech startup, has raised US$12 million in its series A funding round.

The investment was co-led by Capital 2B, Shastra VC, and Kotak Alternate Asset Managers’ Life Sciences Fund I, with participation from IvyCap Ventures and 1Crowd.

The funding will be used to enhance its intellectual property portfolio and support the clinical development of its lead candidate, AVA-NP-695, an ENPP1 inhibitor.

Founded in 2020 by Arun B Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune focuses on small molecule therapies that modulate the immune system to treat cancer and autoimmune disorders.

AVA-NP-695 has shown anti-tumor effects in preclinical models of osteosarcoma, Ewing’s sarcoma, and breast cancer.

The company also plans to advance preclinical development of other candidates in its pipeline.

🔗 Source: Inc42

🧠 Food for thought

1️⃣ India’s biotech funding landscape has evolved from government grants to growing private capital

Avammune’s substantial Series A round represents a stark contrast to India’s biotech funding ecosystem from just a few years ago, which was described as “pathetic” in 2017, with most startups relying primarily on insufficient government grants of just 20-50 lakhs 1.

The current healthtech investment climate shows significant maturation, with the sector securing $716 million across 78 deals in 2024, marking a recovery from the 55% funding decline experienced in 2023 when investments fell to $682.7 million from $1.5 billion 2, 3.

This evolution is particularly notable for companies like Avammune working in complex therapeutic areas that require substantial capital for clinical development, as the funding environment has become more conducive to supporting ambitious biotech ventures beyond initial stages.

The resilience of the healthtech ecosystem is further demonstrated by cumulative funding exceeding $9.9 billion, with projections suggesting continued growth despite previous funding challenges 4.

2️⃣ Indian pharmaceutical sector shifting from generics to innovation-driven growth

Avammune’s focus on novel small molecule therapeutics aligns with India’s broader pharmaceutical industry transformation, which is evolving beyond its traditional strength in generics manufacturing.

Currently valued at approximately $50 billion, the Indian pharmaceutical sector has ambitious plans to reach $450-500 billion by 2047, representing a massive shift that depends on fostering innovation rather than solely focusing on manufacturing capacity 5, 6.